MGIM
ACAD icon

M&G Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

M&G Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$10.3M Buy
+333,824
New +$7.97M 0.04% 195

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

M&G Investment Management's ACAD Position: Q4 2023 in Review

M&G Investment Management opened a new position in Acadia Pharmaceuticals (ACAD) in Q4 2023: 333,824 shares worth $10.3M. The stake represents 0.04% of the portfolio and ranks #195 among its holdings.

275 funds tracked by Wall St. Rank hold ACAD as of Q4 2023.

  • M&G Investment Management held 333,824 shares of Acadia Pharmaceuticals worth $10.3M as of Q4 2023.
  • Acadia Pharmaceuticals was a new M&G Investment Management position in Q4 2023.
  • Acadia Pharmaceuticals made up 0.04% of M&G Investment Management's portfolio in Q4 2023, its #195 holding.
  • 275 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2023.

Based on M&G Investment Management's 13F filing for Q4 2023, filed 8 Feb 2024.